Ulcerative Colitis clinical trials at UC Irvine
2 in progress, 0 open to eligible people
Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
Sorry, not currently recruiting here
The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 [NCT03945188] or APD334-302 [NCT03996369] or APD334-210 [NCT04607837]).
Irvine, California and other locations
Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis
Sorry, in progress, not accepting new patients
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.
Irvine, California and other locations
Last updated: